Scope & Claims Analysis of US Patent 9,855,214: Enalapril Reconstituted Oral Powder with Stability Agent and Colloidal Silicon Dioxide
US Drug Patent 9,855,214 claims a narrowly defined composition-of-matter powder that is reconstituted into an oral liquid and yields a homogenous, physically stable suspension/solution for specified stability windows under controlled storage conditions. The enforceable scope is driven by three claim pillars: (i) enalapril (or pharmaceutically acceptable salt), (ii) a specific stability agent class (lactose/sucrose/mannitol, with dependent claims specifying each), and (iii) colloidal silicon dioxide at defined levels, plus stability requirements for the reconstituted liquid.
What does US 9,855,214 protect: enalapril oral reconstitution powders, liquid stability, or both?
Core claim concept
The independent claim (Claim 1) is directed to:
- A pharmaceutical powder that is reconstituted into an oral liquid formulation.
- The powder “consisting essentially of”:
- enalapril or a pharmaceutically acceptable salt (Claim 2 narrows to enalapril maleate),
- a stability agent (dependent claims restrict to lactose, sucrose, or mannitol),
- colloidal silicon dioxide.
- When reconstituted into the oral liquid, the liquid is:
- homogenous, and
- stable for at least 12 weeks at 25±5° C. and 55±10% relative humidity.
This is a product-by-chemistry and functional performance claim: the powder composition and the post-reconstitution stability performance of the liquid.
“Consisting essentially of” meaning for scope
“Consisting essentially of” allows impurities and minor components that do not materially affect the basic and novel characteristics. Practically, it bars materials that materially change:
- the homogeneity or stability of the reconstituted oral liquid, or
- the powder behavior that results in the claimed liquid stability outcome.
So the enforceable boundary is tighter than “comprising” claims and wider than “consisting of” claims.
What are the key claim limitations that determine infringement risk for enalapril powder reconstitution products?
A. Enalapril component
- Base: enalapril or pharmaceutically acceptable salt (Claim 1).
- Narrow dependent: enalapril maleate (Claim 2).
Implication: A competitor using a different enalapril salt could avoid Claim 1 depending on whether the formulation falls outside “pharmaceutically acceptable salt” interpretations. If the competitor uses a non-“pharmaceutically acceptable” form, it is outside the literal claim.
B. Stability agent selection
Dependent claims specify:
- lactose (Claims 3 and 4)
- sucrose (Claims 3 and 5)
- mannitol (Claims 3 and 6)
Implication: The independent Claim 1 covers any of the enumerated classes as written through the claim set only if Claim 1 is construed to include them via “stability agent.” The dependent claims clearly establish that the patentee treated these as the key stability agent embodiments. A formulation using a different excipient (e.g., sorbitol, xylitol, trehalose, maltodextrin, or a polymeric stabilizer) would likely miss the dependent claims, and could also be outside the “stability agent” as construed if the term is limited by the disclosure/claim history to these specific classes.
C. Colloidal silicon dioxide
- Expressly required in Claim 1.
- Quantified in dependent claims:
- about 1% (w/w) (Claim 9)
- about 0.07 mg/mL in the liquid (Claim 16)
- about 10 mg in a specified powder amount (Claim 17, with the implied package/reconstitution basis)
Implication: Replacing colloidal silicon dioxide with a different glidant/anti-caking agent (e.g., magnesium stearate, fumed silica of different surface characteristics, crosscarmellose sodium, talc) creates an immediate literal risk if the replacement is not “colloidal silicon dioxide” as claimed.
D. Stability performance
- Minimum: 12 weeks stability for the reconstituted oral liquid.
- Conditions: 25±5° C. and 55±10% RH.
- Homogeneity required.
Implication: The claim includes a performance requirement. Noncompliance with stability in that window is a direct non-infringement lever for any literal infringement analysis.
E. Packaging and reconstitution medium
Dependent claims specify reconstitution in:
- water (Claim 11)
- syrup (Claim 12)
Implication: If a competitor’s labeling or product uses a different reconstitution vehicle, dependent-claim literal infringement risk shifts. Claim 1 does not expressly limit the reconstitution medium, but the dependent claims make water/syrup explicit embodiments.
What are the strongest literal claim targets: enalapril maleate + lactose/sucrose/mannitol + ~1% colloidal SiO2?
Independent claim coverage (Claim 1)
Claim 1 is the anchor: it is broadest in excipient options inside the “stability agent” concept, but still requires colloidal silicon dioxide and the 12-week stability/homogeneity outcome.
Dependent claim stacking (Claims 2–10)
The most literal, easy-to-check combinations are:
- Claim 2: enalapril maleate
- Claim 4/5/6: lactose or sucrose or mannitol as the stability agent
- Claims 7–10:
- enalapril content about 14% w/w
- stability agent about 85% w/w
- colloidal silicon dioxide about 1% w/w
- “about 14% / about 85% / about 1%” exact ratio variant
These ratio claims define a highly specific formulation design space.
Liquid composition embodiments (Claims 16–17)
Claim 16 provides a specific concentration set in the reconstituted liquid:
- about 1 mg/mL enalapril
- about 6 mg/mL mannitol
- about 0.07 mg/mL colloidal silicon dioxide
Claim 17 anchors to a powder mass example:
- about 150 mg enalapril
- about 890 mg mannitol
- 10 mg colloidal silicon dioxide
These are valuable infringement handles because they allow comparison against label strengths and reconstitution instructions (milligram/mL and mg per stated reconstitution).
How does Claim 14 expand or narrow coverage versus Claim 1?
Claim 14
Claim 14 is a second independent-style claim with a narrowed excipient set:
- Powder “consisting essentially of”:
- enalapril or salt
- mannitol
- colloidal silicon dioxide
- Same functional stability:
- homogeneous and stable at least 12 weeks at 25±5° C and 55±10% RH.
Net effect: Claim 14 makes mannitol the only stability agent option and thus narrows excipient scope relative to Claim 1, but it provides a cleaner literal path for enalapril/mannitol/SiO2 reconstituted oral liquids.
Claim 15
Adds the ratio embodiment:
- about 14% enalapril or salt
- about 85% mannitol
- about 1% colloidal silicon dioxide
What is the overall claim “map” by formulation variable (ingredient, ratio, dose, stability, vehicle)?
| Variable |
Claim(s) |
Literal elements |
| Active |
1,2 |
enalapril or pharmaceutically acceptable salt; enalapril maleate in 2 |
| Stability agent class |
1,3 |
lactose, sucrose, or mannitol as stability agent |
| Stability agent specific |
4–6 |
lactose (4), sucrose (5), mannitol (6) |
| Colloidal silicon dioxide |
1,9 |
required; about 1% w/w in 9 |
| Ratio (w/w) |
7–10,15 |
~14% enalapril, ~85% stability agent, ~1% SiO2 |
| Reconstitution vehicle |
11–12 |
water (11), syrup (12) |
| Post-reconstitution stability |
1,13,14 |
homogeneous and stable ≥12 weeks at 25±5° C/55±10% RH; ≥6 months ambient/accelerated/refrigerated in 13 |
| Liquid concentration |
16 |
~1 mg/mL enalapril; ~6 mg/mL mannitol; ~0.07 mg/mL SiO2 |
| Example mass |
17 |
~150 mg enalapril, ~890 mg mannitol, 10 mg SiO2 |
What patent landscape questions are answered by the claim structure: formulation patents, method-of-use patents, and generics risk?
1) Is this a method-of-use patent?
No. The claims are directed to a pharmaceutical powder composition and the reconstituted oral liquid properties. There is no dosing regimen or therapeutic use method claimed in the provided claims.
2) Is this a pure composition-of-matter claim or does it hinge on performance?
It is a composition claim with a performance limitation:
- the product must, once reconstituted, produce a homogenous and stable liquid for a specified duration and conditions.
Performance limits can be litigated via stability test evidence on accused products.
3) Formulation-innovation focus
The claims emphasize:
- high loading of enalapril (~14% w/w),
- large bulking/stabilizing excipient (~85% w/w),
- low level colloidal silicon dioxide (~1% w/w),
- homogeneity and stability of the reconstituted oral liquid.
That cluster is consistent with barriers against simple generic “drop-in” substitution.
How could a generic or follow-on product design around US 9,855,214 claims?
Design-around levers
Based strictly on claim text, the most direct design-around opportunities are:
- Eliminate colloidal silicon dioxide or substitute a non-colloidal or non-silicon dioxide glidant/anti-caking agent.
- Use a different stability agent not within lactose/sucrose/mannitol, or use a mixture where the “stability agent” is not one of those types as construed.
- Change the formulation such that the reconstituted liquid fails the stability requirement:
- less than 12 weeks stable under 25±5° C / 55±10% RH,
- or produces a non-homogeneous state.
- Use enalapril in a form that is not within “pharmaceutically acceptable salt,” or otherwise avoid Claim 2’s maleate embodiment (though Claim 1 remains broader on salts).
Design-around constraints
“Consisting essentially of” reduces the ability to add other stabilizers that preserve the same performance while avoiding literal excipient requirements. Any workaround must also maintain the claimed reconstitution homogeneity and stability if the competitor wants to stay competitive, which undercuts the performance-based avoidance strategy unless the competitor accepts reduced shelf life.
What are the claim “strength points” for enforcement based on quantification and testable outcomes?
- Quantified excipient ratios (Claims 7–10 and 15) reduce ambiguity.
- Quantified liquid concentration (Claim 16) creates a measurable match against formulation strength and reconstitution volume.
- Defined stability conditions (Claim 1 and Claim 14) are specific enough for comparative stability study design.
- Homogeneity requirement is directly observable (and often linked to particle settling, caking, or phase separation performance).
Key Takeaways
- US 9,855,214 protects a specific enalapril oral reconstitutable powder system where the reconstituted oral liquid must be homogenous and stable for at least 12 weeks at 25±5° C and 55±10% RH.
- The claim set requires enalapril (or pharmaceutically acceptable salt) plus a stability agent and colloidal silicon dioxide, with dependent claims narrowing to lactose, sucrose, or mannitol, including a mannitol-specific independent claim (Claim 14).
- Strongest infringement anchors are the ~14% w/w enalapril / ~85% w/w stability agent / ~1% w/w colloidal SiO2 composition profile and the reconstituted liquid concentration targets.
- The most obvious design-arounds are removing/altering colloidal silicon dioxide, changing the stability agent class, or ensuring the reconstituted liquid does not meet the 12-week stability + homogeneity performance threshold.
FAQs
-
What exact stability test conditions are required by US 9,855,214 for the reconstituted oral liquid?
At 25±5° C and 55±10% relative humidity for at least 12 weeks, with a homogenous liquid.
-
Does US 9,855,214 require enalapril maleate specifically?
No. Claim 1 covers enalapril or a pharmaceutically acceptable salt; enalapril maleate is a dependent narrowing in Claim 2.
-
Is lactose/sucrose/mannitol interchangeable under the patent claims?
The patent includes dependent claims that separately identify lactose, sucrose, and mannitol as the stability agent (Claims 4–6), with mannitol also forming the basis of Claim 14.
-
What reconstitution media are covered as explicit embodiments?
Water (Claim 11) and syrup (Claim 12) are explicitly claimed as reconstitution vehicles in dependent claims.
-
Can a competitor avoid infringement by changing only the excipient ratios while keeping enalapril and colloidal silicon dioxide?
If the formulation still meets the “consisting essentially of” constraint and the 12-week stability/homogeneity performance, ratio changes may still fall within Claim 1. The explicit ratio-dependent claims (Claims 7–10 and 15) add more literal coverage points but are not the only claim handle.
References (APA)
No external sources were provided in the prompt, and no additional patent-family, prosecution, or Orange Book/FDA data are included in the supplied material.
